Biotechnology Assets Sa Stock Price To Sales
BST Stock | 0.31 0.01 3.13% |
Biotechnology Assets SA fundamentals help investors to digest information that contributes to Biotechnology Assets' financial success or failures. It also enables traders to predict the movement of Biotechnology Stock. The fundamental analysis module provides a way to measure Biotechnology Assets' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotechnology Assets stock.
Biotechnology |
Biotechnology Assets SA Company Price To Sales Analysis
Biotechnology Assets' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition |
Based on the latest financial disclosure, Biotechnology Assets SA has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to sales for all Spain stocks is 100.0% higher than that of the company.
Biotechnology Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotechnology Assets' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotechnology Assets could also be used in its relative valuation, which is a method of valuing Biotechnology Assets by comparing valuation metrics of similar companies.Biotechnology Assets is currently under evaluation in price to sales category among its peers.
Biotechnology Fundamentals
Return On Equity | -0.74 | |||
Return On Asset | -0.0647 | |||
Profit Margin | (0.92) % | |||
Operating Margin | (0.63) % | |||
Shares Outstanding | 48.35 M | |||
Shares Owned By Insiders | 51.21 % | |||
Revenue | 3.28 M | |||
Gross Profit | 3.01 M | |||
EBITDA | (1.04 M) | |||
Book Value Per Share | 0.1 X | |||
Number Of Employees | 33 | |||
Beta | 1.51 | |||
Market Capitalization | 13.64 M | |||
Annual Yield | 0.53 % |
About Biotechnology Assets Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Assets SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Assets using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Assets SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Stock
Biotechnology Assets financial ratios help investors to determine whether Biotechnology Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Assets security.